LONDON, UNITED KINGDOM--(Marketwired - March 3, 2014) - Allerayde SAB, Inc. (OTCQB:ASAB) is putting out this press release to clarify its December 5, 2013 press release in which it stated that it finished second in the Galileo Masters Competition organized by the European Space Agency. The previous press release did not state that the second place finish was awarded in November 2011.
The second place finish was the starting point in product development. ASAB believes that as a result of the competition, ASAB has had the opportunity to access leading research centres in the UK, with the objective of developing a working prototype of its sat-nav device to be integrated with an epinephrine auto-injector.
Allerayde SAB, Inc. (OTCQB:ASAB) announced on December 6, 2013 that the company had secured a grant from the European Space Agency for costs associated with its patent process and creating a working prototype of a new integrated communicator device to be used in conjunction with AAA Pen®. The previous release did not state that the grant was awarded in February 2013.
About Allerayde SAB, Inc.:
Allerayde SAB, Inc. is engaged in the business of developing and manufacturing an innovative anaphylaxis pen product and other consumer health care products for allergy and eczema patients.
The Company's principal product is the AAAPen®. The AAAPen® is a new epinephrine/adrenaline pen for the emergency treatment of anaphylaxis, the severe allergic shock, which may be identified by various rapid onset symptoms following exposure to certain allergens-such as insect venoms, peanuts, seafood, latex, etc.- that have caused symptoms from different level reactions. When the first signs of anaphylaxis being experienced, the AAAPen® shall be used.
Allerayde is also engaged in developing and manufacturing products for the prevention and relief of allergy, asthma and eczema.
Allerayde SAB, Inc. trades on the Over the Counter Market with the ticker symbol ASAB. For more information about the company please visit our website at: www.alleraydesab.com.